Gordofilm Wart Remover Recalled Due to Manufacturing Deviations
Gordofilm Wart Remover by Gordon Laboratories is being recalled nationwide due to Current Good Manufacturing Practice (cGMP) deviations. The FDA classified this as a Class II recall on May 13, 2024.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 2/5 (Moderate).
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall initiated voluntarily due to Current Good Manufacturing Practice deviations. No illnesses, injuries, or hospitalizations are reported in the source. As a voluntary, precautionary recall without documented harm, it meets the Moderate severity category.
Plain-English summary
Gordofilm Wart Remover (salicylic acid 16.7% USP) in 15 cc glass jars has been recalled nationwide. The recall was initiated by the manufacturer, Dercher Enterprises, Inc., doing business as Gordon Laboratories of Upper Darby, Pennsylvania, due to Current Good Manufacturing Practice (cGMP) deviations.
The recall affects 5,247 glass jars with the following lot codes: Lot #F135 (expiration March 2025), Lot #F146 (expiration April 2025), Lot #G103 (expiration January 2026), and Lot #G194 (expiration September 2026). These products were distributed nationwide within the United States.
The FDA classified this as a Class II recall on May 13, 2024. This is a voluntary recall initiated by the firm on April 12, 2024.
The recalled product
- Product
- Gordofilm Wart Remover (salicylic acid 16.7% USP) packaged in 15 cc glass jars, Gordon Laboratories, Upper Darby PA 19082, NDC 10481-3009-01
- Hazard
- Affected units
- 5,247
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (9)
- Lot #: F135
- Exp. Date March 2025
- F146
- Exp. Date April
- 2025
- G103
- Exp. Date January 2026
- G194
- Exp. Date September 2026
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · Dercher Enterprises, Inc., DBA Gordon Laboratories
See all →- SevereGordon Laboratories Recalls MONSEL'S Solution Due to Microbial Contamination
FDA (Drugs) · 2019-07-31
Same hazard · gmp deviation
See all →- HighPrazosin hydrochloride tablets recalled over nitrosamine impurity above limits
FDA (Drugs) · 2026-04-08
- HighPrazosin hydrochloride further lots recalled over nitrosamine impurity levels
FDA (Drugs) · 2026-04-08
- HighPrazosin hydrochloride 100-count bottles recalled over nitrosamine impurity
FDA (Drugs) · 2026-04-08
- ModerateFirst Aid Only hand sanitizing wipes recalled over manufacturing deviations
FDA (Drugs) · 2026-03-11
- ModerateFirst Aid Only BZK antiseptic towelettes recalled over manufacturing deviations
FDA (Drugs) · 2026-03-11
Similar recalls
- ModerateMilbar Recalls DCL Active Mattifying Cleanser Due to GMP Deviations
FDA (Drugs) · 2020-11-25
- ModerateKingskin Salicylic Acid Wart Removal Recall Due to cGMP Deviations
FDA (Drugs) · 2025-04-30
- HighDrug recall: Atorvastatin 20 mg tablets due to manufacturing process deviations
FDA (Drugs) · 2023-04-12
- ModerateMilbar Recalls DCL Clear Skin Anti-Blemish Hydrator Due to GMP Deviations
FDA (Drugs) · 2020-11-25
- ModerateMilbar Recalls DCL Alpha Beta Gel Toner Due to GMP Deviations
FDA (Drugs) · 2020-11-25
- ModerateNitroglycerin Sublingual Tablets Recalled for CGMP Deviations
FDA (Drugs) · 2025-04-16